Blue Trust Inc. Acquires 24,875 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Blue Trust Inc. boosted its holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) by 56.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,122 shares of the company’s stock after acquiring an additional 24,875 shares during the quarter. Blue Trust Inc. owned 0.16% of DiaMedica Therapeutics worth $375,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC lifted its position in DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after acquiring an additional 70,070 shares in the last quarter. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Price Performance

NASDAQ DMAC opened at $5.76 on Friday. The business’s fifty day moving average price is $5.48 and its 200-day moving average price is $4.53. The stock has a market capitalization of $246.30 million, a price-to-earnings ratio of -10.29 and a beta of 1.46. DiaMedica Therapeutics Inc. has a 1-year low of $2.14 and a 1-year high of $6.41.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.